Comparative Transcriptome Profiles of Human Blood in Response to the Toll-like Receptor 4 Ligands Lipopolysaccharide and Monophosphoryl Lipid A

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Luan, Liming ^a   Patil, Naeem K ^a   Guo, Yin ^a   Hernandez, Antonio ^a   Bohannon, Julia K ^a   Fensterheim, Benjamin A ^a   Wang, Jingbin ^a   Xu, Yaomin ^a   Enkhbaatar, Perenlei ^b   Stark, Ryan ^a   Sherwood, Edward R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGIC FACTOR; IMMUNOLOGICAL ADJUVANT; LIPID A; LIPOPOLYSACCHARIDE; PHOSPHORYL LIPID A; TOLL LIKE RECEPTOR 4; TRANSCRIPTOME;

ANALOGS AND DERIVATIVES; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG EFFECT; HUMAN; LEUKOCYTE; METABOLISM; MICROARRAY ANALYSIS; NORMAL HUMAN;

ADJUVANTS, IMMUNOLOGIC; HEALTHY VOLUNTEERS; HUMANS; IMMUNOLOGIC FACTORS; LEUKOCYTES; LIPID A; LIPOPOLYSACCHARIDES; MICROARRAY ANALYSIS; TOLL-LIKE RECEPTOR 4; TRANSCRIPTOME;

EID: 85008312068     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep40050     Document Type: Article

References (35)

1. Raetz, C. R. et al. Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. Faseb J 5, 2652-2660 (1991).
2. Raetz, C. R. & Whitfield, C. Lipopolysaccharide endotoxins. Annu Rev Biochem 71, 635-700, doi: 10.1146/annurev. biochem.71.110601.135414 (2002).
3. Caroff, M., Karibian, D., Cavaillon, J. M. & Haeffner-Cavaillon, N. Structural and functional analyses of bacterial lipopolysaccharides. Microbes Infect 4, 915-926 (2002).
4. Bohannon, J. K., Hernandez, A., Enkhbaatar, P., Adams, W. L. & Sherwood, E. R. The immunobiology of toll-like receptor, 4 agonists: from endotoxin tolerance to immunoadjuvants. Shock 40, 451-462, doi: 10.1097/SHK.0000000000000042 (2013).
5. Schweizer, H. P. Understanding efflux in Gram-negative bacteria: opportunities for drug discovery. Expert opinion on drug discovery 7, 633-642, doi: 10.1517/17460441.2012.688949 (2012).
6. Poltorak, A. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085-2088 (1998).
7. Hirschfeld, M. et al. Signaling by toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect Immun 69, 1477-1482, doi: 10.1128/IAI.69.3.1477-1482.2001 (2001).
8. Yamamoto, M. & Akira, S. Lipid A receptor TLR4-mediated signaling pathways. Adv Exp Med Biol 667, 59-68 (2009).
9. Plociennikowska, A., Hromada-Judycka, A., Borzecka, K. & Kwiatkowska, K. Co-operation of TLR4 and raft proteins in LPSinduced pro-inflammatory signaling. Cellular and molecular life sciences: CMLS 72, 557-581, doi: 10.1007/s00018-014-1762-5 (2015).
10. Singer, M. et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama 315, 801-810, doi: 10.1001/jama.2016.0287 (2016).
11. Lehner, M. D. et al. Improved innate immunity of endotoxin-tolerant mice increases resistance to Salmonella enterica serovar typhimurium infection despite attenuated cytokine response. Infection and immunity 69, 463-471, doi: 10.1128/IAI.69.1.463-471.2001 (2001).
12. Murphey, E. D., Fang, G. & Sherwood, E. R. Endotoxin pretreatment improves bacterial clearance and decreases mortality in mice challenged with Staphylococcus aureus. Shock 29, 512-518, doi: 10.1097/shk.0b013e318150776f (2008).
13. Fan, H. & Cook, J. A. Molecular mechanisms of endotoxin tolerance. J Endotoxin Res 10, 71-84, doi: 10.1179/096805104225003997 (2004).
14. Murphey, E. D., Fang, G., Varma, T. K. & Sherwood, E. R. Improved bacterial clearance and decreased mortality can be induced by LPS tolerance and is not dependent upon IFN-gamma. Shock 27, 289-295, doi: 10.1097/01.shk.0000245024.93740.28 (2007).
15. Johnson, A. G., Tomai, M., Solem, L., Beck, L. & Ribi, E. Characterization of a nontoxic monophosphoryl lipid A. Rev Infect Dis 9 Suppl 5, S512-516 (1987).
16. Alving, C. R., Peachman, K. K., Rao, M. & Reed, S. G. Adjuvants for human vaccines. Current opinion in immunology 24, 310-315, doi: 10.1016/j.coi.2012.03.008 (2012).
17. Astiz, M. E., Galera, A., Saha, D. C., Carpati, C. & Rackow, E. C. Monophosphoryl lipid A protects against gram-positive sepsis and tumor necrosis factor. Shock 2, 271-274 (1994).
18. Astiz, M. E., Rackow, E. C., Kim, Y. B. & Weil, M. H. Monophosphoryl lipid A induces tolerance to the lethal hemodynamic effects of endotoxemia. Circulatory shock 33, 92-97 (1991).
19. Romero, C. D. et al. The Toll-like receptor 4 agonist monophosphoryl lipid a augments innate host resistance to systemic bacterial infection. Infect Immun 79, 3576-3587, doi: 10.1128/IAI.00022-11 (2011).
20. Bohannon, J. K. et al. Role of G-CSF in monophosphoryl lipid A-mediated augmentation of neutrophil functions after burn injury. Journal of leukocyte biology 99, 629-640, doi: 10.1189/jlb.4A0815-362R (2016).
21. Hernandez, A. et al. The role of MyD88-and TRIF-dependent signaling in monophosphoryl lipid A-induced expansion and recruitment of innate immunocytes. Journal of leukocyte biology, doi: 10.1189/jlb.1A0216-072R (2016).
22. Schulke, S. et al. MPLA shows attenuated pro-inflammatory properties and diminished capacity to activate mast cells in comparison with LPS. Allergy 70, 1259-1268, doi: 10.1111/all.12675 (2015).
23. Schulke, S. et al. A Fusion Protein Consisting of the Vaccine Adjuvant Monophosphoryl Lipid A and the Allergen Ovalbumin Boosts Allergen-Specific Th1, Th2, and Th17 Responses In Vitro. J Immunol Res 2016, 4156456, doi: 10.1155/2016/4156456 (2016).
24. Chilton, P. M., Embry, C. A. & Mitchell, T. C. Effects of Differences in Lipid A Structure on TLR4 Pro-Inflammatory Signaling and Inflammasome Activation. Front Immunol 3, 154, doi: 10.3389/fimmu.2012.00154 (2012).
25. Embry, C. A., Franchi, L., Nunez, G. & Mitchell, T. C. Mechanism of impaired NLRP3 inflammasome priming by monophosphoryl lipid A. Sci Signal 4, ra28, doi: 10.1126/scisignal.2001486 (2011).
26. Vanden Berghe, T. et al. Simultaneous targeting of IL-1 and IL-18 is required for protection against inflammatory and septic shock. Am J Respir Crit Care Med 189, 282-291, doi: 10.1164/rccm.201308-1535OC (2014).
27. Varma, T. K. et al. Endotoxin priming improves clearance of Pseudomonas aeruginosa in wild-type and interleukin-10 knockout mice. Infect Immun 73, 7340-7347, doi: 10.1128/IAI.73.11.7340-7347.2005 (2005).
28. Mata-Haro, V. et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316, 1628-1632, doi: 10.1126/science.1138963 (2007).
29. Astiz, M. E. et al. Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: a prospective, double-blind, randomized, controlled trial. Crit Care Med 23, 9-17 (1995).
30. Biswas, S. K. & Lopez-Collazo, E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 30, 475-487, doi: 10.1016/j.it.2009.07.009 (2009).
31. Schwarz, T. F. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Expert Rev Vaccines 7, 1465-1473, doi: 10.1586/14760584.7.10.1465 (2008).
32. Monie, A., Hung, C. F., Roden, R. & Wu, T. C. Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics 2, 97-105 (2008).
33. Gomes, N. E. et al. Lipopolysaccharide-induced expression of cell surface receptors and cell activation of neutrophils and monocytes in whole human blood. Braz J Med Biol Res 43, 853-858 (2010).
34. Sabroe, I., Jones, E. C., Usher, L. R., Whyte, M. K. & Dower, S. K. Toll-like receptor (TLR)2 and TLR4 in human peripheral blood granulocytes: a critical role for monocytes in leukocyte lipopolysaccharide responses. Journal of immunology 168, 4701-4710 (2002).
35. Romero, C. D. et al. The Toll-like receptor 4 agonist monophosphoryl lipid a augments innate host resistance to systemic bacterial infection. Infection and immunity 79, 3576-3587, doi: 10.1128/IAI.00022-11 (2011).